Viking Therapeutics Gains Ground with Promising Oral Weight Loss Treatment

Shares of Viking Therapeutics experienced substantial gains following the release of impressive Phase 2 trial results for its oral formulation of VK2735. The study demonstrated an average weight reduction of up to 12.2 percent after 13 weeks, providing compelling evidence for the drug candidate’s efficacy.

The VENTURE-Oral study, which enrolled 280 participants, delivered consistently positive outcomes without showing a plateau effect. Up to 97 percent of treated individuals achieved at least a 5 percent reduction in body weight, while 80 percent of participants lost 10 percent or more.

Safety data remained encouraging, with 98 percent of reported adverse events classified as mild to moderate. These were primarily gastrointestinal issues, which typically emerged at the beginning of treatment and diminished as dosing continued.

Dual-Formulation Strategy Creates... Read more...